Ascendis Pharma

Pipeline Progress And Global Launches Will Expand Market Reach

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

27 Nov 24

Updated

28 Nov 25

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

54.5%

7D

-3.2%

Loading

1Y

54.5%

7D

-3.2%

You can edit this narrative until Nov 29 9:10 AM. Then, changes will post as Updates.

Author's Valuation

US$257.6620.3% undervalued

AnalystConsensusTarget Fair Value

Shared on 28 Nov 25

Fair value Decreased 0.43%

ASND: Expanding Real-World Uptake Will Drive Sustained Strength Despite Recent Headlines

Ascendis Pharma’s analyst price target was adjusted slightly to $257.66 from $258.77, as analysts cite positive trends in Yorvipath adoption and broader market confidence despite recent headline risks. Analyst Commentary Recent analyst commentary on Ascendis Pharma signals broad confidence in the company’s prospects, particularly with respect to growing Yorvipath adoption and commercial execution.

Shared on 14 Nov 25

Fair value Increased 5.36%

ASND: Strong Uptake Set To Drive Sustained Outperformance Amid Payor Clarity

Ascendis Pharma's analyst price target has been raised from approximately $245.61 to $258.77 per share. This change reflects greater confidence among analysts due to solid Yorvipath uptake, improved profit projections, and continued reassurance over recent safety concerns.

Shared on 05 Oct 25

Fair value Decreased 2.18%

The consensus analyst price target for Ascendis Pharma was adjusted from $251.09 to $245.61. This reflects slightly more conservative growth and fair value assumptions as analysts evaluated competitive dynamics in hypoparathyroidism and the evolving outlook for the company’s key therapy, Yorvipath.

Shared on 10 Aug 25

Fair value Increased 6.71%

Ascendis Pharma's consensus price target has been raised to $250.41, driven by strong commercial momentum for Yorvipath, positive pipeline developments—particularly in rare diseases—and compelling interim COACH trial data in achondroplasia, reinforcing analyst confidence in both near-term execution and long-term upside. Analyst Commentary Bullish analysts highlight strong commercial momentum and uptake for Yorvipath in hypoparathyroidism.

Shared on 01 May 25

Fair value Increased 8.49%

Shared on 23 Apr 25

Fair value Increased 0.0092%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

Fair value Decreased 2.26%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

Fair value Increased 3.84%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Increased 1.91%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

Fair value Increased 0.15%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

Fair value Decreased 0.095%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 12 Mar 25

Fair value Decreased 8.61%

AnalystConsensusTarget has decreased revenue growth from 72.3% to 61.0%, decreased profit margin from 36.6% to 31.4%, increased future PE multiple from 24.2x to 33.1x and decreased shares outstanding growth rate from 0.1% to 0.0%.

AnalystConsensusTarget Fair Value

US$257.66

20.3% undervalued

Future estimation in

% p.a.

0

Decrease

Increase

Current revenue growth rate

33.75%

Biotech revenue growth rate

9.24%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

6.80%

Calculation

€945.76m

Earnings '28

x

18.61x

PE Ratio '28

=

€17.60b

Market Cap '28

€17.60b

Market Cap '28

/

65.02m

No. shares '28

=

€270.65

Share Price '28

€270.65 Share Price '28

Discounted to 2025 @ 6.81% p.a.

=

€222.13

Fair Value '25

€222.13 Fair Value '25

Converted to USD @ 1.1596 EUR/USD Exchange Rate

=

US$257.57

Fair Value '25